Home › Blog › Weight Loss › Wegovy UK

Wegovy UK: Injection and Weight Loss Pill Guide

Wegovy UK is available in two forms: the once-weekly semaglutide injection, licensed here since 2023, and the once-daily Wegovy pill, which the MHRA approved on 11 June 2026 as the first oral GLP-1 medicine licensed in the UK for weight management. Both contain the same active ingredient, semaglutide, and both are prescription-only medicines available privately following a clinical assessment, or on the NHS through specialist services for a much narrower group of patients. This guide covers eligibility, how the injection and the tablet differ, dosing for both, what they cost, side effects, and how to obtain either safely from a regulated UK pharmacy.

Wegovy UK: the short answers

This guide explains everything UK patients need to know about Wegovy, including how the injection and the pill compare, eligibility, NHS access, private costs, dosing for both forms, side effects, switching, and how to choose a safe provider.

✍️ Written by Shadeia Younis, Superintendent Pharmacist (GPhC No. 2052119) and the Slinic Clinical Team

Last medically reviewed: 26 July 2026  ·  Last updated: 26 July 2026  ·  Prices last verified: 26 July 2026

Jump to

Wegovy UK at a glance

This guide has been written and clinically reviewed by UK-registered pharmacy professionals at Slinic. Treatment is supplied through Brierfield Late Night Pharmacy, GPhC-registered premises No. 1033729. This guide provides general information and does not replace personal medical advice or an individual clinical assessment.

What is Wegovy?

Wegovy is a brand name. The medicine inside it is semaglutide, made by Novo Nordisk. Semaglutide is a GLP-1 receptor agonist — it mimics glucagon-like peptide-1, a hormone your gut releases after eating that signals fullness to the brain.

In the UK, Wegovy is licensed for weight management in adults as an adjunct to a reduced-calorie diet and increased physical activity. That word adjunct is not filler. The medicine is not licensed as a standalone intervention, and the trial results everyone quotes were achieved alongside structured dietary and lifestyle support, not instead of it.

Wegovy, Ozempic and Rybelsus: three products, one molecule

This is the single most common source of confusion in UK weight management, and it matters because the products are not interchangeable.

Ozempic is not a weight-loss medicine in the UK. It contains semaglutide, but it is licensed for type 2 diabetes. Prescribing it for weight loss is off-label, and demand for that purpose has contributed to supply shortages affecting people who need it for diabetes. If you want semaglutide for weight management, the licensed products are Wegovy injection and Wegovy pill.

Rybelsus is not the Wegovy pill. Both are oral semaglutide, but Rybelsus is licensed only for type 2 diabetes and only up to 14 mg. The Wegovy pill is a higher-strength formulation licensed specifically for weight management. Swapping one for the other is not a substitution a patient or a prescriber should make.

The medicine versus the service

Semaglutide is the same molecule regardless of which UK pharmacy supplies it, provided it is genuine licensed stock from the authorised supply chain. What varies enormously between providers is everything around it: the depth of the clinical assessment, who reviews your case, whether anyone follows up, how side effects are managed, and what happens when progress stalls or you want to stop. Comparing providers on price alone compares the identical component and ignores the variable one.

Wegovy injection versus Wegovy pill

Both deliver semaglutide. The practical differences are substantial, and neither is universally better.

Who each may suit

The injection may suit you better if you would rather think about treatment once a week than every morning, you are comfortable with needles or willing to become so, your mornings are unpredictable, or you already take oral medicines whose timing would be complicated by the fasting window.

The tablet may suit you better if you have a genuine needle phobia, you travel frequently and find cold-chain logistics a problem, you already have a settled morning routine that a fasting window fits into, or you have found injection-site reactions troublesome.

Is the Wegovy pill available in the UK?

Yes, but with an important distinction between approval and supply that a lot of coverage has blurred.

What has happened

The MHRA approved oral semaglutide on 11 June 2026 for weight management in adults with a BMI of 30 or above, or 27 to under 30 with at least one weight-related comorbidity. It is the first oral GLP-1 receptor agonist licensed for weight management in the UK, and the UK was the third jurisdiction to approve it, after the United States and the United Arab Emirates.

It is available through regulated private providers, prescribed following a clinical assessment, alongside a reduced-calorie diet and increased physical activity.

Supply is being introduced in phases. Novo Nordisk has described a phased UK rollout intended to keep supply consistent. The lower titration strengths entered circulation first, with the higher strengths following progressively. In practice this means a new patient starting at the bottom of the titration ladder is generally unaffected, but availability of a specific strength at a specific moment can vary.

Approval, supply and funding are three different things

If a provider is promising immediate supply of a particular strength, ask them to confirm current stock rather than assuming. And if a website is offering oral semaglutide without a prescription or a clinical assessment, that is not a legitimate UK route regardless of what the product page says.

How Wegovy works

Semaglutide is a GLP-1 receptor agonist. It mimics and amplifies a hormone your body already produces after eating, and it works on several fronts at once.

What it is not

Semaglutide is not a stimulant, does not raise your metabolic rate, and does not block absorption of what you eat. Weight loss happens because appetite falls and energy intake follows. If intake does not fall — because portion sizes stay the same out of habit, or because reduced appetite is offset by high-calorie liquids — results will be limited whatever the dose.

Why the two forms feel different

The weekly injection produces relatively steady drug levels across the week. The daily tablet produces a daily peak and trough. Some people notice appetite effects more variably through the day on the tablet, particularly early in treatment. Both reach comparable exposure at maintenance doses when taken correctly, which is why the fasting rules for the tablet matter so much.

Why response varies

Variation between individuals is substantial. Some people notice a dramatic change in appetite within the first week or two; others notice little until a higher dose. Starting weight, baseline eating patterns, metabolic health, sleep, stress, activity and other medicines all appear to contribute, and the reasons are not fully understood. You cannot predict your own result from someone else's.

How much weight can people lose on Wegovy?

The evidence base for semaglutide is large and genuinely strong. It is also routinely misquoted, so it is worth separating what the trials found from what an individual should expect.

The injection: STEP 1

STEP 1 studied once-weekly semaglutide 2.4 mg in adults with overweight or obesity, without type 2 diabetes, over 68 weeks alongside lifestyle intervention. Mean weight reduction was approximately 14.9%, compared with approximately 2.4% on placebo, and around two-thirds of participants lost at least 10% of their body weight.

The injection: STEP 4

STEP 4 is the trial that matters most if you are thinking about stopping. Participants took semaglutide for 20 weeks, then either continued or switched to placebo. Those who continued kept losing weight. Those who switched to placebo regained a substantial proportion of what they had lost. The effect depends on continued exposure — there is no period after stopping during which the benefit persists on its own.

The higher-dose injection: STEP UP

A 7.2 mg weekly strength is also licensed in the UK, studied in the STEP UP trial, which found greater average weight reduction than 2.4 mg in the population studied. It is not a starting dose and is only considered once someone is established on 2.4 mg. See the dedicated 7.2 mg section below.

The tablet: OASIS 4

OASIS 4 studied oral semaglutide 25 mg in 307 adults with overweight or obesity without diabetes over 64 weeks. Mean weight reduction was approximately 16.6%, compared with approximately 2.2% on placebo. This is the trial that supported the MHRA approval, and it is why the tablet is described as broadly comparable to the injection rather than inferior to it.

What the averages do not tell you

An average contains a wide spread. Some participants lost far more, some far less. A mean figure presented as an expected personal result is misleading.

Trial conditions are not everyday conditions. Participants received structured dietary support, regular contact and monitoring at an intensity most people do not have.

Results depend on more than the medicine. Starting weight, dose reached, consistency, diet, activity, sleep, other conditions and other medicines all influence the outcome.

Duration matters. These are figures at 64 to 68 weeks. Results at 12 weeks look very different.

The timeline below is a general illustration rather than a prediction. Individual responses vary considerably, and dose changes should only follow clinical review.

No provider can accurately predict how much weight an individual will lose. Published figures describe averages across study populations, not guaranteed personal outcomes.

Semaglutide, Wegovy and type 2 diabetes

Semaglutide is licensed in the UK for two entirely separate purposes under different brand names, and the distinction has practical consequences if you have diabetes.

Different products. Wegovy and the Wegovy pill are licensed for weight management. Ozempic and Rybelsus contain the same molecule but are licensed for type 2 diabetes. They are not substitutes for one another, and the strengths differ.

Different prescribing route. Semaglutide for type 2 diabetes is prescribed through diabetes care, usually your GP practice or a diabetes specialist, as part of managing blood glucose. That route is not subject to the specialist weight management service bottleneck that limits NHS Wegovy.

Different clinical priorities. When prescribed for diabetes the focus is HbA1c, glycaemic control and cardiovascular risk, with weight reduction as a welcome secondary benefit. When prescribed for weight management the priorities reverse.

Private weight-management prescribing for someone with type 2 diabetes is common and entirely legitimate — BMI 27 or above with type 2 diabetes meets the licensed criteria. It requires your HbA1c, current medicines and diabetes history to form part of the assessment, and coordination with your GP on any dose adjustments.

Why some people lose weight faster than others

Two people on the same dose of the same medicine, starting at similar weights, can end up with markedly different results. This is the question patients ask most often once treatment is under way, and it deserves a proper answer rather than a shrug.

Factors that genuinely influence response

What you eat during the appetite window. The medicine reduces hunger. It does not decide what fills the smaller amount you now eat. Two people eating 1,500 calories can have very different outcomes depending on protein, fibre and how much comes from liquids that bypass fullness signalling entirely.

Whether you drink your calories. This is the most common invisible cause of a poor response. Semaglutide slows gastric emptying and increases satiety from food volume. Sugary drinks, alcohol, syrup coffees and smoothies deliver calories without triggering any of that.

Muscle mass and what happens to it. Someone who resistance trains and eats adequate protein loses proportionally more fat and less lean tissue, and holds a higher energy requirement while doing it. Someone who eats very little of everything loses muscle alongside fat and slows their own progress.

Sleep. Short or disrupted sleep raises appetite signalling and reduces the effect the medicine is trying to produce. It is unglamorous and it matters.

Starting weight and body composition. Percentage weight loss and absolute weight loss are different measures, and people comparing themselves to each other are frequently comparing different things.

Other medicines. Several commonly prescribed medicines — some antidepressants, antipsychotics, steroids, certain diabetes treatments and some beta blockers — are associated with weight gain or make loss harder. This is worth reviewing rather than assuming the weight-loss medicine has failed.

Untreated conditions. Undiagnosed hypothyroidism, poorly controlled diabetes, and conditions affecting mobility all influence what is achievable.

How consistently the medicine is actually taken. Adherence data across GLP-1 treatment shows a close, near-linear relationship between doses taken and weight lost. This is the single biggest modifiable factor, and it is the one people are least likely to report accurately.

Who may qualify for Wegovy privately in the UK?

Private eligibility follows the terms of the UK licence, then narrows according to each provider's clinical governance. The licensed criteria are the same for the injection and the tablet.

Weight-related conditions that may qualify at BMI 27 to under 30

• Type 2 diabetes
• Prediabetes
• High blood pressure
• Dyslipidaemia, including raised cholesterol
• Obstructive sleep apnoea
• Cardiovascular disease

Lower thresholds for some ethnic backgrounds

For people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family background, a lower BMI threshold is commonly applied — usually reduced by around 2.5 kg/m² — because cardiometabolic risk occurs at lower BMI in these populations. NICE applies this adjustment in its NHS criteria. Whether and how a private provider applies it is a matter of their clinical policy.

What else is assessed

Full medical history, including anything you might assume is irrelevant.

Every medicine you take — prescription, over-the-counter, herbal and supplements. This matters more for the tablet than most people realise, because the fasting window interacts with the timing of other oral medicines.

Pregnancy status and plans. Semaglutide is not recommended in pregnancy and needs establishing before treatment, not after.

Identity and weight verification. A legitimate provider verifies who you are and confirms your weight rather than accepting a self-reported figure unchecked. Methods vary — photo verification, video consultation, or both.

Any current GLP-1 treatment. Two GLP-1 medicines must never be taken together, and that includes the Wegovy injection and the Wegovy pill.

Eating disorder history, current or past.

Meeting the criteria does not guarantee treatment

A prescriber can decline — because of your medical history, because a symptom needs investigating first, because another treatment would be safer, or because the overall picture does not support prescribing. A provider that guarantees approval before assessing you is telling you something important about how seriously it takes the assessment.

Wegovy and specific weight-related conditions

Several conditions are both a reason you might qualify at a lower BMI and a reason treatment needs particular care.

Obstructive sleep apnoea

A recognised qualifying condition at BMI 27 to under 30. Weight reduction frequently improves symptoms, and CPAP pressure requirements can change as weight falls. If you use CPAP, tell the service that manages it — settings may need reviewing rather than staying fixed for the duration.

High blood pressure

Also a qualifying condition. Blood pressure commonly falls with weight reduction, which has a practical consequence: if you take antihypertensives you may become over-treated as you lose weight. Dizziness on standing is usually the first sign. Report it rather than accepting it, because it generally means a medication review is due rather than that the weight-loss treatment is the problem.

Polycystic ovary syndrome

PCOS is not itself on the licensed list, but insulin resistance, prediabetes and raised BMI commonly accompany it and those may qualify. Two things matter here. Weight reduction can restore ovulation in people who were not previously ovulating, so fertility may return unexpectedly — and semaglutide is not recommended in pregnancy. Contraception planning is genuinely important, and should happen before the first dose rather than after.

Prediabetes

A qualifying condition with a preventive dimension: weight reduction reduces progression to type 2 diabetes. Your prescriber may want a baseline HbA1c.

Raised cholesterol and dyslipidaemia

A qualifying condition. Lipid profiles commonly improve with weight reduction. If you take a statin, continue it unless your prescriber advises otherwise — losing weight is not a reason to stop cardiovascular medication on your own initiative.

Fatty liver disease

Common alongside obesity, and weight reduction is the main intervention. Known liver disease requires individual assessment as part of your consultation.

Gallstones

Worth flagging separately because it runs the other way. Rapid weight loss from any cause increases gallstone risk, and gallbladder events are a recognised effect of GLP-1 treatment. A history of gallstones is not automatically a barrier, but it is something your prescriber needs to know, and new upper right abdominal pain during treatment should be reported rather than tolerated.

Who may not be suitable for Wegovy?

Three categories are often presented as one undifferentiated list. They are not equivalent, and the distinction is useful.

Licensed contraindications

Wegovy must not be used if you have known serious hypersensitivity to semaglutide or to any of the excipients in the product.

Warnings and precautions in the product information

Pregnancy. Semaglutide is not recommended during pregnancy. Because of its long half-life, guidance is to discontinue well in advance of a planned pregnancy — confirm the specific interval with your prescriber and the current patient information leaflet.

Breastfeeding. Discuss with your prescriber before starting; the decision will be based on your circumstances and the current product information.

Pancreatitis. Acute pancreatitis has been reported with GLP-1 receptor agonists, and the MHRA has issued strengthened warnings on this. A history of pancreatitis requires careful assessment, and any symptoms suggestive of it during treatment need urgent medical attention.

Gallbladder disease and gallstones. Rapid weight loss from any cause increases gallstone risk. Symptoms need reporting rather than tolerating.

Severe gastrointestinal disease, including gastroparesis. Because semaglutide slows gastric emptying, pre-existing severe GI disease needs individual assessment.

Kidney impairment. Gastrointestinal fluid loss can precipitate acute kidney injury in susceptible people. Dehydration is the mechanism, which is why fluid intake matters more than it sounds like it should.

Liver impairment. Requires individual assessment.

Diabetic retinopathy. Rapid improvement in blood glucose control has been associated with temporary worsening of diabetic retinopathy. Relevant if you have diabetes and existing eye disease, and a reason to report sudden visual changes promptly.

Hypoglycaemia risk. Semaglutide alone rarely causes low blood sugar, but risk rises substantially alongside insulin or a sulfonylurea. Those doses may need adjusting by whoever manages your diabetes.

Planned surgery or procedures with sedation or anaesthesia. Delayed gastric emptying increases aspiration risk. Tell your surgical and anaesthetic team well in advance — professional guidance on how far ahead to stop varies, so have the conversation early rather than the night before.

Thyroid C-cell tumour history. The product information addresses personal or family history of medullary thyroid carcinoma and Multiple Endocrine Neoplasia syndrome type 2. Raise any relevant family history at assessment.

Provider-specific clinical exclusions

Beyond the licence, providers apply their own criteria reflecting their clinical governance and the limits of a remote service — commonly current or past eating disorders, certain mental health presentations, complex polypharmacy, or situations better managed face to face. These are legitimate clinical decisions but they are policy rather than universal medical fact, which is why one clinic may decline where another accepts.

Other weight-loss medicines

Wegovy must not be combined with another GLP-1 receptor agonist — including Mounjaro, Ozempic, Saxenda or Victoza — or with other weight-loss medicines, unless specifically directed by a prescriber managing the whole picture. The injection and the pill must never be taken together either.

Wegovy injection doses

The maintenance dose of 2.4 mg once weekly is reached by starting low and escalating in steps, to reduce the likelihood of gastrointestinal symptoms.

How escalation works in practice

Four weeks at each step is the standard interval. It is the point at which a dose increase may be considered, not a schedule everyone must follow. Staying longer at a dose is a legitimate clinical decision and often the right one.

Escalation is not automatic. It should follow a review of how you are responding and how well you are tolerating the current dose. Increasing while significant symptoms persist usually worsens those symptoms without improving results.

Steps should not be skipped. Jumping strengths without prescriber authorisation substantially increases the risk of adverse effects.

2.4 mg is not compulsory. If appetite is well controlled and weight is coming down at a lower dose, there may be no clinical reason to increase.

Follow the directions given by your own prescriber.

Why treatment sometimes does not work

Most people respond well. A minority do not, and the reasons are usually identifiable rather than mysterious. In rough order of how often they turn out to be the explanation:

1. Doses not taken consistently. The most common cause and the least often reported accurately. Adherence and weight loss track each other closely.
2. Tablet taken incorrectly. With food, with coffee, or too close to other morning medicines. Absorption falls substantially and the month looks like non-response.
3. Liquid calories. Drinks bypass the satiety mechanism the medicine works through, so the appetite reduction never translates into reduced intake.
4. Portion sizes unchanged out of habit. Serving the same amount and finishing it, because that is what a meal has always looked like.
5. Not enough time at an adequate dose. Judging the medicine at week six, on a titration dose, is judging it before it has been given a chance.
6. Another medicine working against it. Some antidepressants, antipsychotics, steroids and diabetes treatments make loss harder. Worth reviewing before concluding the treatment failed.
7. An untreated condition. Undiagnosed thyroid disease and poorly controlled diabetes both change what is achievable.
8. Genuine non-response. A real but small group. Response to one GLP-1 does not predict response to another, so this is a reason to review options rather than to stop looking.

When increasing the dose is not the right answer

There is a strong assumption among patients that a stalled result means the dose should go up. Sometimes it should. Often it should not, and escalating into the wrong situation makes things worse rather than better.

Reasons a prescriber may hold the dose

You are still having significant side effects. Increasing while nausea, vomiting or diarrhoea are unresolved reliably worsens them, and the most common consequence is that the patient abandons treatment altogether. Settling first and increasing later usually gets further.

You are still losing weight steadily. If the current dose is working, there is no clinical argument for adding side-effect risk and cost to achieve something already happening.

The plateau is short. Weight loss is not linear. Two or three weeks without movement is normal variation, not a plateau, and reacting to it with a dose increase treats noise as signal.

Something other than the dose explains it. Liquid calories, a new medicine, poor sleep, a period of low adherence, or tablet technique. Escalating without checking these means raising the dose to compensate for a fixable problem.

Intake has dropped too far already. If you are struggling to eat adequately, more appetite suppression is the opposite of what is needed.

A symptom needs investigating first. New abdominal pain, in particular, is a reason to pause and assess rather than escalate.

What a clinician looks at before agreeing an increase

• How long you have actually been at the current dose, and whether the minimum interval has passed
• The trend over several weeks rather than the most recent weigh-in
• Whether side effects have settled or are ongoing
• Whether doses have been taken consistently, and honestly — this is the question worth answering accurately even if it is uncomfortable
• For tablet patients, whether the fasting routine has been followed properly
• What has changed in diet, activity, sleep, stress or other medicines
• Whether your other conditions or medicines need reviewing as weight changes
• Whether the goal is still realistic and still what you want

Wegovy 7.2 mg: the higher-dose option

A 7.2 mg once-weekly strength is licensed in the UK, roughly three times the standard 2.4 mg maintenance dose. It is the highest licensed semaglutide dose available, and it is frequently misunderstood, so it is worth being precise about what it is and who it is for.

It is not a starting dose

This is the single most important point. Nobody begins treatment on 7.2 mg. The standard titration still applies in full — 0.25 mg, then 0.5, 1, 1.7 and 2.4 mg, with the usual minimum interval at each step. Only after you are established on 2.4 mg does 7.2 mg become a question your prescriber might consider, and typically only after you have been on 2.4 mg for a period and the clinical picture supports going further.

Who it may be considered for

Broadly, someone who has completed the full titration, is tolerating 2.4 mg well, and whose weight loss has slowed or fallen short of what their clinical situation calls for. It is a response-driven decision, not an upgrade to request.

It is generally not appropriate if you had significant side effects at lower doses, if you have not completed the standard escalation, or if there is something in your medical history that makes a higher exposure unwise. Your prescriber decides, based on your response and tolerability.

What the evidence shows

The 7.2 mg dose was studied in STEP UP, a phase 3b trial of around 1,400 adults with obesity and without type 2 diabetes, over 72 weeks, comparing 7.2 mg against 2.4 mg and placebo alongside lifestyle support.

Two honest caveats. First, the headline percentage varies between published figures depending on which statistical analysis is quoted, which is why a range is given above rather than a single number. Second, the additional average benefit over 2.4 mg is real but moderate — for someone weighing 100 kg it amounts to roughly a few extra kilograms across more than a year. The more striking finding is the shift at the top end: substantially more people reached 25% or more.

Side effects at the higher dose

The overall safety profile in STEP UP was broadly consistent with 2.4 mg, and gastrointestinal effects followed the familiar pattern — most common during escalation, easing over time.

One finding is specific enough to be worth knowing about in advance. Dysaesthesia — an altered or tingling sensation in the skin — was reported by close to a quarter of participants on 7.2 mg, considerably more than at 2.4 mg. In the large majority of cases it resolved while treatment continued. It is not dangerous, but it is unsettling if nobody has mentioned it to you, and it is the kind of thing that leads people to stop treatment unnecessarily. Report it to your prescriber if it happens rather than assuming something has gone wrong.

Is it better than Mounjaro?

A reasonable question, and not one with a clean answer. The 7.2 mg strength narrows the gap in average weight reduction between semaglutide and tirzepatide, but the two have never been compared head to head at those doses in a single trial. Cross-trial comparison is not valid evidence. Which suits an individual depends on response, tolerability, cost, availability and medical history — not on lining up percentages from separate studies.

See our Mounjaro UK guide for the tirzepatide picture, and our Mounjaro versus Wegovy comparison.

What is the best Wegovy dose?

There is no universally best dose. The aim is the lowest dose that produces a good result and that you tolerate well.

Higher doses produce greater average weight reduction across populations — that is a real finding. But averages describe groups, not individuals, and several reasons argue against automatically escalating to the top of the ladder.

Some people respond strongly at lower doses. If appetite is well controlled and weight is coming down steadily, there is no clinical reason to increase simply because a higher strength exists.

Side effects generally increase with dose. A dose that produces good results but makes you feel unwell is not a good dose, particularly if it leads you to abandon treatment.

Faster is not better. Escalating quickly raises the likelihood of gastrointestinal side effects without reliably improving the final outcome.

Cost usually scales with dose. Being on the lowest effective dose has a financial dimension too.

The decision belongs with your prescriber, based on your response, tolerance, progress and medical history.

Wegovy tablet doses and how to take them

The tablet has its own titration ladder, and the numbers look nothing like the injection's because oral absorption differs so much. The two connect at the top: 2.4 mg weekly by injection corresponds to 25 mg daily by tablet, and the licence allows a direct switch between them.

How to take the tablet correctly

1. Take it once daily, in the morning, on an empty stomach after fasting for at least 8 hours — for most people this means first thing on waking.
2. Swallow it whole with a sip of plain water only. Do not split, crush or chew it.
3. Do not take it with any other liquid, and not with tea, coffee, juice or milk.
4. Wait before eating, drinking anything else, or taking other oral medicines, for the interval specified in your patient information leaflet.
5. Take it at roughly the same time each day.
6. If you take other regular morning medicines, plan the sequence with your pharmacist before you start.

Missing a tablet

A missed daily tablet is skipped entirely. Do not take two tablets to catch up, and do not take a missed tablet later in the day once you have eaten, because the fasting condition has gone. Resume your normal single daily dose the following morning. If you miss several consecutive days, contact your prescriber before resuming, as a lower restart dose may be appropriate.

Switching between the injection and the tablet

The licence allows people established on the 2.4 mg once-weekly injection to move directly to the 25 mg once-daily tablet on their prescriber's advice. Moving in the other direction, or from a lower injection dose, is a clinical judgement rather than a fixed conversion. Either way the two must not overlap, and the switch needs planning around the timing of your last injection.

What happens at your first consultation

Knowing what to expect makes the assessment easier to complete properly, and completing it properly is what makes it safe.

What you will be asked

• Your height and current weight, and how your weight has changed over time
• Previous weight-loss attempts, including any medication
• Your full medical history, including anything you might assume is irrelevant
• Every medicine you take — prescription, over-the-counter, herbal and supplements, with the times of day you take them
• Whether you are pregnant, breastfeeding or planning a pregnancy
• Any history of eating disorders
• Whether you have surgery or a procedure planned
• Your alcohol intake
• Family history where relevant to the product warnings
• Your morning routine, if you are considering the tablet — the fasting window has to fit your actual life

What to have ready

• An accurate current weight — weigh yourself rather than estimating
• A list of your medicines with doses and timings
• Photo ID
• If transferring from another provider: your current medicine, dose, how long you have been on it, and evidence such as a dispensing label or order history

Why complete answers matter more than fast ones

The assessment exists to catch situations where semaglutide would be unsafe for you specifically. Leaving something out does not improve your chance of approval in any way that helps you — it raises the chance of being prescribed something that interacts badly with a medicine you take, or worsens a condition you have. Incomplete assessments usually produce a request for more information, which delays things rather than speeding them up.

What happens next

A UK-registered prescriber reviews your submission. The outcome is approval, a request for further information or a video consultation, or a decision that treatment is not appropriate. That last outcome is not a rejection of you — it is the assessment doing its job.

How to use the Wegovy pen

This is an overview. The Instructions for Use supplied with your pen are the authoritative source and should be read fully before your first injection.

• Once weekly, same day each week. Any time of day, with or without food.
• Check the pen before use. The liquid should be clear and colourless. Do not use it if it is cloudy, discoloured, contains particles, has been frozen, or looks damaged.
• Use a new needle every time. Reusing needles blunts the tip, increases pain and injection-site reactions, and risks blockage.
• Prepare the dose exactly as described in the Instructions for Use.
• Inject into an approved site and hold the pen in place for the full count specified, so the complete dose is delivered.
• Remove the needle immediately afterwards and dispose of it in a sharps bin. Never store the pen with a needle attached.
• Never share your pen, even with a new needle.
• If the pen appears faulty, do not work around it. Contact your pharmacy.

Where to inject

Wegovy is injected subcutaneously — into the fat layer just under the skin, not into muscle or a vein.

• The abdomen, avoiding the area immediately around the navel
• The front of the thigh
• The upper arm

Rotate sites with each injection. Repeated use of the same spot can cause lumps, hardening or changes in the fat layer, which can affect absorption. Avoid skin that is bruised, tender, red, hardened, scarred or affected by a skin condition. If you also inject insulin, use a different site for each medicine.

How much does Wegovy cost in the UK?

Private Wegovy costs in the UK vary widely between providers, and the advertised figure is frequently not what you end up paying over a year.

Why the headline price and the real cost differ

Dose-based pricing. Most providers charge more for higher strengths. Since almost everyone starts at the bottom of the ladder, the advertised price is usually the lowest you will ever pay.

Subscription models. Some providers require a monthly commitment with a minimum term or a cancellation window.

First-order discount codes. Very common. A discount on the first order that reverts from month two changes the annual figure considerably.

Consultation and delivery charges. Included by some providers, added at checkout by others.

Consumables. Needles and a sharps bin are needed for the injection and are not always supplied.

The only meaningful comparison is total cost over twelve months at the dose you are likely to be on, with everything included.

Slinic's Wegovy prices

Wegovy injection prices

Wegovy pill prices

Prices last verified: July 2026

What this means over a year

The figure that matters is not the starting price, it is what you pay once you reach a maintenance dose and stay there. On the injection, most people settle at 2.4 mg. On the tablet, most reach 25 mg. Those are the numbers to budget against, not the entry price — and it is worth doing that arithmetic before you start rather than discovering it at month four.

It is also worth noting that the tablet costs less at maintenance than the injection does, which is unusual in this market and largely reflects the absence of cold-chain handling. If cost is a significant factor and the daily fasted routine suits you, that difference is real and worth raising at your assessment.

Slinic prices are fixed for 2026 with no subscription and no minimum term, and do not change mid-treatment. Prices are subject to clinical approval before dispatch. For a full breakdown and comparison against other UK providers, see our provider price comparison and our weight-loss treatment pages.

Can you get Wegovy on the NHS?

The injection, yes — but through a much narrower route than most people expect. The tablet, not currently at all.

Three things that are often conflated

The MHRA licence says who the medicine may legally be prescribed to: adults with BMI 30 or above, or 27 to under 30 with a weight-related comorbidity.

The NICE recommendation says who the NHS should fund it for. NICE technology appraisal TA875, published in March 2023, recommends semaglutide for weight management within NHS specialist weight management services, subject to specific criteria and with a funding limit.

Local commissioning determines what is actually available where you live, and this varies considerably.

NHS criteria for the Wegovy injection

• Initiated within a specialist weight management service — commonly described as Tier 3 — not by your GP directly
• BMI thresholds set by TA875, with the usual 2.5 kg/m² downward adjustment for certain ethnic backgrounds
• At least one weight-related comorbidity
• Funded for a maximum of two years
• Continuation typically requires a demonstrated response at review

Your GP can refer you to a specialist service but cannot generally initiate treatment themselves under this route. Waiting times for specialist weight management services vary from weeks to well over a year depending on area.

The four UK nations

NICE appraisals apply to England and, through separate arrangements, generally to Wales and Northern Ireland. Scotland has its own process through the Scottish Medicines Consortium. Local implementation, service availability and waiting times differ across all four nations, so if you are outside England, check your own nation's current position rather than assuming the arrangements described here apply.

The Wegovy pill on the NHS

Not available. NHS funding requires a separate NICE appraisal, which is under way for oral semaglutide. Access is not expected during 2026, and if recommended would come with its own eligibility criteria. At present the tablet is a private-prescription treatment only.

If you think you may qualify for NHS treatment

Speak to your GP practice about your weight and any weight-related conditions and ask what the local referral pathway is. If you are prescribed on the NHS, standard prescription charge arrangements apply and you may be exempt. This section reflects guidance current at the time of writing, and arrangements in this area have changed repeatedly — check the current NICE and NHS positions before making decisions.

Your first weeks on Wegovy: what to expect

The opening month is when most people either settle into treatment or decide it is not for them. Knowing what is normal helps you tell the difference between an adjustment period and a genuine problem.

On the injection

On the tablet

The first month looks different, because the routine is the harder part rather than the dose. Most people find the fasting window is the thing that takes adjusting to, not the medicine. It is worth setting an alarm, keeping a glass of water by the bed, and deciding in advance what time you will actually be able to eat breakfast, because working that out on day one tends to produce a week of missed or badly-taken doses.

If by the end of the first month you have repeatedly taken the tablet with food, taken it late, or skipped it because the routine did not fit, that is worth raising at review rather than pushing on. Switching to the weekly injection is a reasonable answer and not a failure.

When does Wegovy start working?

Pharmacologically, semaglutide begins acting from the first dose. What you notice, and when, is a different question.

Appetite changes usually come first. Many people notice reduced hunger and earlier fullness within the first week or two, often before the scales move meaningfully. The reduction in food preoccupation is frequently described as the first clear sign.

Visible weight change usually takes longer. The starting doses on both forms are titration doses, used to introduce treatment gradually rather than to deliver full effect.

Weight fluctuates day to day. Fluid, hormonal cycles, salt intake and bowel habit all move the number independently of fat loss. Weekly measurement at a consistent time is far more useful than daily.

Limited early change does not mean failure. Some people notice little during the first weeks and considerably more as the dose steps up. Continue only as directed by your prescriber, who will review response and tolerability before deciding whether the dose should change.

Response should be assessed over an appropriate period. If there has been no meaningful change after several months at an adequate dose taken consistently, that warrants a proper review — which might mean a dose adjustment, a look at what else is going on, a switch of form, or a discussion about whether a different medicine would suit you better.

One point specific to the tablet: before concluding it is not working, confirm you have been taking it correctly. A tablet taken with breakfast, with coffee, or too close to other morning medicines may not have been absorbed properly, and that is a fixable problem rather than a treatment failure.

Wegovy side effects

Most side effects are gastrointestinal, most appear during titration or shortly after a dose increase, and most settle as the body adjusts. In the clinical trials nausea was the most frequently reported effect, followed by diarrhoea and vomiting, and these were typically mild to moderate.

Common effects and how to manage them

Reducing side effects

• Eat smaller portions. Because gastric emptying is slower, a normal-sized meal can feel like a large one. This is the single most effective adjustment for most people.
• Eat slowly and stop when full. Fullness signals arrive earlier than you are used to.
• Avoid very fatty and fried food, particularly in the days after a dose increase.
• Keep fluids up. Reduced appetite usually reduces drinking too, and mild dehydration worsens nausea, fatigue and constipation.
• Do not increase your dose while significant symptoms persist. Discuss staying longer at the current step.
• Ask a pharmacist before adding any remedy. Delayed gastric emptying affects how oral medicines are absorbed — and if you are on the tablet, anything taken in the morning interacts with the fasting window.
• Watch for dehydration — dark urine, passing much less urine than usual, dizziness on standing, persistent thirst.

Serious symptoms requiring urgent medical help

Call 999 or go to A&E for:

• Severe abdominal pain, particularly persistent pain or pain radiating to the back — this can indicate pancreatitis, and the MHRA has issued strengthened warnings about this risk with GLP-1 medicines
• Signs of a serious allergic reaction: swelling of the face, lips, tongue or throat, difficulty breathing, widespread rash with feeling unwell
• Severe dehydration: confusion, fainting, unable to keep any fluid down
• Persistent vomiting with severe abdominal pain and inability to pass stool or wind, which can indicate bowel obstruction
• Severe hypoglycaemia in anyone taking insulin or a sulfonylurea: confusion, seizure, loss of consciousness

Contact NHS 111 or your prescriber promptly for:

• Vomiting or diarrhoea that will not settle
• Pain in the upper right abdomen, yellowing of the skin or eyes, or pale stools — possible gallbladder or liver involvement
• Passing much less urine than usual, or other signs of possible kidney injury after a period of vomiting or diarrhoea
• Sudden changes in vision, particularly if you have diabetes
• Significant changes in mood, or thoughts of harming yourself
• Any symptom that worries you

Tell your surgical and anaesthetic team well in advance of any planned operation or procedure involving sedation. Delayed gastric emptying increases aspiration risk, and they need to know.

Wegovy and other medicines

This is not an exhaustive list. Tell your prescriber about every prescription medicine, over-the-counter product, herbal remedy and supplement you take.

Insulin. Combining semaglutide with insulin substantially increases hypoglycaemia risk. Insulin doses may need adjusting by whoever manages your diabetes.

Sulfonylureas (gliclazide, glimepiride and similar). The same concern applies.

Oral medicines generally. Delayed gastric emptying can alter how quickly oral medicines are absorbed. Most relevant where timing matters or where the therapeutic range is narrow.

Levothyroxine, warfarin and other narrow-therapeutic-index medicines. More frequent monitoring may be appropriate — discuss with the clinician managing that treatment.

Blood pressure medicines. As weight falls, blood pressure often falls with it. Dizziness on standing is usually the first sign you may be over-treated, and it is a reason for a medication review rather than something to endure.

Any other oral medicine, if you take the tablet. The fasting window before and after your daily dose has to be planned around your other morning medicines. Go through this with a pharmacist before you start rather than working it out afterwards.

Other GLP-1 medicines. Never combine. This includes taking the Wegovy injection and the Wegovy pill together.

Wegovy, contraception and pregnancy

Wegovy is not recommended during pregnancy.

If you are planning to become pregnant, treatment should be stopped well in advance of conception. Semaglutide has a long half-life of roughly a week, so the interval is longer than people generally expect. Confirm the specific period with your prescriber and the current patient information leaflet.

If you become pregnant while taking Wegovy, stop the medicine and contact your prescriber or GP straight away.

If you are breastfeeding or planning to, discuss this with your prescriber before starting.

Contraception matters more than people expect here. Weight reduction can restore ovulation in people who were not previously ovulating — this is common in polycystic ovary syndrome — which means fertility can return unexpectedly while you are taking a medicine that is not recommended in pregnancy. If there is any possibility of pregnancy, plan contraception before your first dose rather than after.

What should you eat while taking Wegovy?

Appetite reduction creates an opportunity and a risk at the same time. The opportunity is that eating less becomes far easier. The risk is that eating less of everything — including protein and micronutrients — produces poor nutrition, muscle loss and fatigue.

• Prioritise protein. When total intake falls, protein is the thing most worth protecting, because it helps preserve lean muscle during weight loss.
• Include fibre from vegetables, fruit, pulses and wholegrains, adjusted to your symptoms.
• Keep some healthy fats — olive oil, nuts, oily fish — while noting that very fatty meals commonly worsen nausea early on.
• Choose wholegrain carbohydrates over refined where you can.
• Eat smaller portions more often rather than three large meals.
• Drink enough. Reduced appetite usually reduces fluid intake without you noticing, and dehydration is the mechanism behind several of the more serious problems.
• Do not crash diet. Combining very low calorie intake with semaglutide raises the risk of nutritional deficiency, muscle loss, fatigue, hair thinning and gallstones. The medicine already reduces intake substantially; severe restriction on top is counterproductive.

How much protein do you need?

Protein requirements vary by body size, age, activity level and health status, so a single universal target is not useful and for some people would be actively wrong.

Why it matters. Weight loss from any cause includes some lean tissue as well as fat. Adequate protein combined with resistance exercise limits that considerably.

Food first. Meat, fish, eggs, dairy, beans, lentils, tofu and pulses. Supplements are worth considering only where food intake genuinely cannot meet requirements.

Older adults generally need more protein per kilogram than younger adults to maintain muscle. Anyone with kidney disease must get individual advice before increasing protein — the general advice does not apply.

Exercise while taking Wegovy

• Any movement counts. Walking is genuinely valuable and needs no equipment.
• Include resistance exercise. This is the single most effective thing you can do to protect muscle while losing weight — bodyweight work, bands or weights, a couple of times a week.
• Build gradually. Large sudden increases in activity while eating considerably less is a route to exhaustion.
• Stay hydrated, particularly after any gastrointestinal symptoms.
• Scale back when unwell rather than pushing through nausea or low intake.
• If you have diabetes, be aware of hypoglycaemia risk around exercise, particularly on insulin or a sulfonylurea.

Can you drink alcohol on Wegovy?

There is no absolute prohibition, but several reasons for caution.

• It can worsen nausea and reflux, particularly in the days after a dose increase.
• It contributes calories — often a significant number, and ones that do not trigger fullness.
• It can affect blood glucose, which matters more if you take insulin or a sulfonylurea.
• It contributes to dehydration, compounding the effect of any gastrointestinal symptoms.
• Heavy drinking carries risks to the pancreas and liver worth considering with a medicine that has pancreatitis among its recognised risks.
• Many people report wanting it less. A reduction in alcohol interest is commonly described by people on GLP-1 medicines, and is worth noting rather than fighting.

Many people drink moderately without difficulty. Discuss your own situation with your prescriber.

Wegovy, fasting and Ramadan

Fasting while taking semaglutide raises practical and safety questions, and the two forms are affected very differently.

On the injection

• Hydration is the main concern. Semaglutide can cause gastrointestinal fluid loss, and a long daily fast on top of that increases dehydration risk. Rehydrating properly during non-fasting hours matters more than usual.
• Injection timing is flexible. The dose can be given at any time of day, so schedule it for whatever suits.
• Appetite reduction can make it hard to eat enough in a short eating window. Prioritising protein and fluid becomes more important, not less.
• If you take insulin or a sulfonylurea, get individual advice before fasting. That combination carries a real hypoglycaemia risk needing planning with your diabetes team.

On the tablet

The tablet needs more thought, because it already requires a fasted state and a waiting period before eating or drinking. During Ramadan that has to be worked around the pre-dawn meal and the evening break, and the arrangement will not be obvious. Plan it with your prescriber or pharmacist in advance rather than improvising during the first week, and be aware that switching temporarily to the injection is a legitimate option to discuss.

The same considerations apply to intermittent fasting patterns generally. Combining aggressive time restriction with a medicine that already substantially reduces intake tends to produce poor nutrition and fatigue rather than better results.

How should Wegovy be stored?

Storage differs completely between the two forms, and this is one of the practical advantages of the tablet.

The injection

• Before first use: store in a refrigerator between 2°C and 8°C. Do not freeze.
• After first use: the pen may be kept for a defined in-use period at room temperature or returned to the fridge — check the exact period and temperature range in the patient information leaflet supplied with your pen, as this differs between products and presentations.
• Never use a pen that has been frozen, even if it has thawed and looks normal.
• Keep it in the original carton to protect it from light.
• Never store the pen with a needle attached — this can cause leaking, block the needle and allow air into the cartridge.
• Do not use it if the liquid is cloudy, discoloured or contains particles.

The tablet

• Store at room temperature in the original blister and packaging.
• No refrigeration required, and no cold chain needed for delivery or travel.
• Keep it dry — do not decant tablets into a pill organiser unless your pharmacist confirms that is appropriate, because the packaging protects the formulation.
• Check the storage details in your patient information leaflet.

Travelling with Wegovy

If a pen has been stored incorrectly, contact your pharmacy rather than using it and hoping.

What to do if you miss a dose of Wegovy

The advice is completely different for the two forms, and applying the injection rule to the tablet, or the reverse, causes real problems.

Missed injection

The five-day window exists because semaglutide has a half-life of roughly seven days. Within that window, taking the missed dose keeps drug levels in the right range. Beyond it, you risk two near-full doses overlapping.

Never take two injections to make up for a missed one.

To change your injection day permanently, plan it with your prescriber, keeping the minimum interval between doses set out in your patient information leaflet.

Missed tablet

Skip it entirely and take your next tablet at the normal time the following morning. Do not take two tablets to catch up, and do not take a missed tablet later the same day — once you have eaten or drunk anything other than that sip of water, the fasting condition needed for absorption has gone.

If you miss several consecutive days, contact your prescriber before resuming rather than restarting at your previous dose.

If you keep missing doses

Work out why. Inconsistent dosing produces inconsistent results, and adherence data across GLP-1 treatment shows a close relationship between how consistently the medicine is taken and how much weight is lost. If the cause is side effects, cost, or a routine that does not fit — particularly the tablet's fasting window — there are usually solutions, including switching form.

Practical problems and what to do

Monitoring, blood tests and clinical reviews

Treatment does not end at the first prescription, and what happens afterwards varies far more between providers than the medicine itself does.

What ongoing review should cover

• Weight change and over what period
• Whether side effects are settling, persisting or worsening
• Whether the current dose is right, or whether staying longer is better than escalating
• Any new symptoms, particularly abdominal pain
• Any new medicines — and for tablet patients, whether the morning routine is still working
• Whether your other conditions or medicines need reviewing as weight changes, particularly blood pressure and diabetes medicines
• Eating pattern, protein intake and activity

Do you need blood tests?

Routine blood monitoring is not universally required for weight-management semaglutide in the way it is for some medicines. Your prescriber may request baseline or interval tests depending on your circumstances — for example if you have diabetes, kidney or liver concerns, or if a symptom needs investigating. Testing is a clinical judgement based on your history, not a fixed schedule.

Be cautious of a provider offering no clinical review at all, and equally of one marketing extensive testing you have not been given a clinical reason for.

What to report between reviews

Do not wait for your next review to report severe abdominal pain, persistent vomiting, signs of dehydration, reduced urine output, symptoms of an allergic reaction, or sudden visual changes. Those need attention when they happen.

Wegovy versus Mounjaro

The most common comparison in UK weight management, and the one most often reduced to a single percentage.

What the comparison does and does not tell you. SURMOUNT-5 compared tirzepatide against semaglutide 2.4 mg directly and found greater average reduction with tirzepatide. That is real head-to-head evidence and it should not be dismissed. But it compared 2.4 mg, not 7.2 mg, and averages describe groups rather than individuals. Plenty of people do very well on semaglutide, some tolerate it better than tirzepatide, and some have already tried tirzepatide and want an alternative.

The practical differences that often decide it: Wegovy offers a needle-free option, Mounjaro does not. Tirzepatide has the stronger average trial result. Cost, supply, tolerability and your own response matter more than either.

See our full Mounjaro UK guide and our Mounjaro versus Wegovy comparison.

Switching to or from Wegovy

Patients move between treatments and between providers regularly. None of it should be improvised.

Switching provider

Transferring pharmacy is normal and does not mean starting treatment again from scratch. You may be able to continue at your current dose, depending on your treatment history and how long you have been at that strength.

• You will need evidence of your current treatment — a dispensing label, prescription record, letter from your previous provider, or order history showing dose and dates. Without it, a prescriber cannot safely continue you at a higher dose.
• The clinician will review continuity and tolerability — how long you have been treated, at what doses, how you tolerated them, and whether there has been a gap.
• A prolonged gap may mean restarting lower. This is a safety decision, not an administrative one.
• No supply is guaranteed until the assessment is complete.

Wegovy injection to Wegovy tablet

The licence allows people established on the 2.4 mg weekly injection to transition directly to the 25 mg daily tablet on their prescriber's advice. If you are on a lower injection dose, the appropriate tablet starting point is a clinical judgement rather than a fixed conversion. Timing matters: the switch has to be planned around your last injection so the two do not overlap.

Wegovy tablet to Wegovy injection

Also possible, and also a clinical judgement based on the tablet dose you have reached, how long you have been on it, and how you have tolerated it. There is no published patient-facing conversion table, and there should not be one, because the decision depends on more than the numbers.

Wegovy and Mounjaro

Switching between semaglutide and tirzepatide happens frequently, usually because of response, tolerability, cost or supply. There is no official published dose-equivalence between them for weight management. Any switch is a clinical judgement based on your current dose, duration, tolerability and response.

See our Mounjaro UK guide, our Wegovy to Mounjaro switching guide, and our provider comparisons: Slinic vs Boots, Slinic vs MedExpress, Slinic vs Simple Online Pharmacy, Slinic vs VOY and Slinic vs Juniper.

How clinicians decide whether to continue treatment

Continuation is a decision at every review, not a default. A prescriber is weighing several things.

Is it working? Clinical guidance for weight-management medicines generally looks for a meaningful response within a defined period at an adequate dose — NICE uses a 5% threshold at six months for NHS semaglutide. Private prescribing is not bound by that figure, but the principle is sound: treatment that is not producing a response after a fair trial deserves a rethink rather than indefinite continuation.

Is it tolerated? Ongoing significant side effects at a stable dose are a reason to change something, whether that is the dose, the form, or the medicine.

Has anything changed medically? New symptoms, new diagnoses, a planned pregnancy, planned surgery, or a new medicine can all change the picture.

Is it still the right tool? Someone who has reached their goal and is maintaining, someone whose circumstances have changed, or someone for whom cost has become unsustainable are all having a different conversation from someone mid-treatment.

What does the patient want? This belongs on the list. Treatment is a decision made with you, and a prescriber who never asks what you actually want from it is not doing the job properly.

What happens when you stop Wegovy?

Appetite generally returns. The effect on appetite signalling stops when the medicine does.

Weight regain is common. STEP 4 demonstrated this directly: participants switched to placebo regained a substantial proportion of what they had lost, while those who continued kept losing.

This is not a personal failure. Obesity is a chronic condition, and treatments for chronic conditions generally stop working when stopped. The same is true of blood pressure medicine.

Habits built during treatment matter enormously. People who used the treatment period to establish sustainable eating patterns, regular activity and resistance training tend to retain more of their result.

Stopping should be planned, not impulsive. If cost, side effects or lack of progress are prompting the thought, say so at review — there may be options you have not considered, including switching form or dose.

Is Wegovy a lifelong treatment?

There is no single answer, and anyone giving you one is oversimplifying. Obesity is recognised as a chronic, relapsing condition, and for some people long-term pharmacological support is appropriate in the same way it would be for hypertension. For others a defined treatment period followed by maintenance through diet, activity and behavioural change works well.

What determines the right approach: how well the medicine works for you, how well you tolerate it, your other conditions, cost, and what you want. All of that should be reviewed periodically rather than decided once at the start. Stopping treatment is not failure, and needing to continue is not failure either.

What makes maintenance more likely to work

• Resistance exercise established during treatment rather than started at the point of stopping
• Eating patterns you actually want to keep, rather than ones you are enduring
• Adequate protein maintained throughout
• A planned taper and review rather than an abrupt stop
• Realistic expectations — some regain is common and is not failure

NHS versus private Wegovy treatment

NHS weight management services provide high-quality multidisciplinary care, and where you qualify and can access one without a prohibitive wait, that route is well worth pursuing. The reason most people go private is availability rather than quality: the current criteria and capacity exclude the large majority of people who meet the licensed threshold.

Wegovy versus diet and lifestyle change alone

Worth addressing directly, because it is the comparison most people have already tried, often several times.

The placebo groups in the semaglutide trials are the useful comparison here. Those participants received structured dietary support, regular contact and monitoring at an intensity almost nobody gets in real life, and still averaged only a few percent. That is not a comment on their effort. It reflects that the body defends its weight through hormonal appetite signalling, and that lifestyle change alone is working against that signal rather than with it.

The point is not that lifestyle change does not work. It is that the medicine and the lifestyle change do different jobs, which is exactly why the licence describes it as an adjunct rather than a replacement. Nobody who takes Wegovy and changes nothing else gets the trial result.

Wegovy versus weight-loss surgery

A fair question for anyone considering options at higher BMI, and one that pharmacy sites usually avoid because surgery is not something they can sell.

These are not competing options so much as different tools for different situations, and increasingly they are used together — medication before surgery, after surgery, or instead of it where surgery is not appropriate or not wanted.

If your BMI is in the range where surgery is considered, it is worth having that conversation with your GP rather than ruling it out because a medication is easier to start. A pharmacy cannot assess you for surgery, and any provider implying medication is straightforwardly better than an operation they cannot offer is not giving you a balanced picture.

How to buy Wegovy safely online in the UK

Buying prescription medicine online is entirely legitimate when the provider is properly regulated. The difficulty is that legitimate and illegitimate providers can look similar at a glance, and demand for semaglutide has created a substantial illegitimate market. The MHRA has repeatedly warned about falsified pens entering the UK through unofficial channels, and there have been documented cases of people being hospitalised after using products bought outside the regulated supply chain.

Absolute red flags

• Social media sellers. Instagram, TikTok, Facebook groups and messaging apps are not legal supply routes for prescription medicines. A seller operating there is by definition operating outside UK medicines law.
• Any offer to supply without a prescription. If a site will sell you Wegovy without a clinical assessment and a prescriber, it is not a legitimate UK pharmacy. This is the clearest single indicator that whatever arrives did not come through the authorised supply chain.
• Imported product. Medicines sourced outside the UK may not be licensed here, may not be the formulation approved for UK use, and carry no guarantee that cold chain was maintained.
• Anyone else's medication. Sharing prescription medicines is unsafe and illegal. Pens must never be shared even with a new needle, because of blood-borne infection risk.
• Prices that make no commercial sense. Genuine UK-licensed semaglutide has a wholesale cost. A price far below the market range is a strong signal the product is not what it claims to be.
• "Compounded" or "generic" semaglutide. There is no licensed generic semaglutide in the UK. Anything marketed that way is not a UK-licensed medicine.

A ten-point check on any provider

1. Confirm it is registered premises. Find the GPhC registration number and look it up on the GPhC register yourself. A number displayed on a website proves nothing until you verify it independently.
2. Check who runs it. A legitimate pharmacy names its superintendent pharmacist and provides a real UK address and a working phone number.
3. Confirm a genuine clinical assessment. You should be asked detailed questions about medical history, current medicines and pregnancy status. A three-question form is not a clinical assessment.
4. Confirm a prescription is required. If it is not, stop.
5. Check who the prescriber is — a UK-registered doctor, pharmacist prescriber or nurse prescriber, registered with the GMC, GPhC or NMC.
6. Check cold chain for the injection. Ask how refrigeration is maintained in transit.
7. Read the payment terms before ordering. Is it a subscription? Can you cancel? Does the price change after month one? Are consultation or delivery charges added at checkout?
8. Check what ongoing clinical support is included. Who reviews dose increases? Who do you contact when side effects appear?
9. Be wary of guarantees. No legitimate provider can guarantee approval before assessing you.
10. Read the regulatory signals in the right order. GPhC registration is the statutory requirement and matters most. CQC registration applies to certain provider types. LegitScript is a useful additional signal but is a private certification scheme, not a substitute for statutory regulation.

Slinic dispenses through Brierfield Late Night Pharmacy, GPhC-registered premises No. 1033729. Our Superintendent Pharmacist, Shadeia Younis, is personally registered under GPhC No. 2052119. Premises registration and individual professional registration are two separate things, and both can be checked independently on the GPhC register.

What patients tell us matters most

Recurring themes from patient feedback about treatment at Slinic. These are the things people mention unprompted, and they are worth knowing about because they are the parts of a service you cannot assess from a price list.

• Personalised consultations. Being assessed as an individual rather than processed through a form, and having a real conversation about whether treatment is right for them.
• No pressure to increase the dose. Being supported to stay at a dose that is working rather than being moved up on a schedule.
• Transparent fixed pricing. Knowing what the next month costs, with no subscription and no first-order discount that quietly expires.
• Fast delivery. Treatment arriving promptly once approved, in appropriate packaging.
• Ongoing clinician support. Being able to reach a pharmacist with a question during treatment, rather than only at the point of ordering.
• Starter materials and supplies included. Needles and swabs provided with treatment rather than as an extra purchase.

None of these are things a medicine does. They are things a service does, and they are the main reason people transfer between providers while staying on exactly the same treatment.

Wegovy treatment at Slinic

• Online clinical assessment reviewed by a UK-registered prescriber
• Both the Wegovy injection and the Wegovy pill available, subject to clinical assessment and current supply
• The full injection range stocked, including the 7.2 mg higher-dose pen where clinically appropriate
• Video consultation where required by our clinical pathway
• Prescribing decisions made by GMC- and GPhC-registered clinicians
• Monthly clinical reviews included
• Needles and swabs supplied with injectable treatment
• No subscription and no minimum term
• Fixed published 2026 prices that do not change mid-treatment — injections from £99.99 per pen, tablets from £99.00 per month
• Direct access to a pharmacist for clinical questions during treatment
• Discreet UK delivery, temperature-controlled where the treatment requires it
• Support for patients transferring from another provider
• Dispensed from GPhC-registered premises No. 1033729, an NHS-contracted community pharmacy
• Led by a SCOPE-certified Superintendent Pharmacist with 25 years of pharmacy experience

Most approved orders are prepared promptly, with dispatch subject to clinical approval, stock availability, identity verification and delivery-service cut-off times. Completing an assessment does not guarantee that treatment will be approved.

How to begin

1. Complete the online clinical assessment. Answer fully and honestly — it only protects you if it is complete.
2. Provide the required verification: identity, current weight, and evidence of previous treatment if you are transferring.
3. A clinician reviews your information.
4. Attend a video consultation where our clinical pathway requires one.
5. Receive a prescribing decision — approval, a request for more information, or a decision that treatment is not appropriate.
6. Discuss which form suits you if you are eligible for both the injection and the tablet.
7. Approved treatment is prepared for dispatch.
8. Complete a clinical review before each repeat supply.

Completing an assessment does not guarantee approval. Wegovy is a prescription-only medicine, and clinical safety takes priority over speed.

Common Wegovy mistakes to avoid

Taking the tablet with food or a drink other than water. The single most consequential mistake specific to the oral form.

Escalating too quickly. The minimum interval at each step is a minimum, not a target.

Doubling up after a missed dose. Never, on either form.

Taking a missed tablet later in the day. Once you have eaten, the fasting condition has gone.

Using the injection and the tablet together. They contain the same medicine.

Working out your own dose when switching form. There is a licensed transition from the 2.4 mg injection to the 25 mg tablet, but any other switch is a prescriber decision, not arithmetic.

Sharing a pen. Unsafe regardless of needle changes.

Reusing needles. A new one every time.

Buying outside the regulated supply chain. The most dangerous item on this list.

Ignoring severe abdominal pain. This needs urgent attention, not waiting to see.

Letting yourself get dehydrated. Easily done when appetite drops, and the mechanism behind several serious complications.

Eating too little protein. Costs you muscle.

Stopping abruptly with no plan. Regain is likely without one.

Not disclosing a medicine or condition. The assessment only protects you if it is complete.

Comparing your progress with other people's. Response varies enormously and the comparison rarely helps.

Common myths about Wegovy

When Wegovy is not the right answer

A page like this has an obvious commercial incentive to present treatment as the solution. It is not always.

If your BMI is below the licensed threshold, treatment is not appropriate and no legitimate provider will supply it.

If your relationship with food or your body is the primary difficulty, a medicine that suppresses appetite may make things worse rather than better. Current or past eating disorders need appropriate support first, and a good assessment screens for this.

If you are looking for a short-term fix before an event, this is the wrong tool. Meaningful change takes many months, and stopping is commonly followed by regain.

If you cannot sustain the cost, repeatedly starting and stopping is worse than not starting. Budget for the maintenance dose price, not the starting dose price.

If you know the tablet's daily fasted routine will not fit your life, say so rather than starting it and hoping. Taken incorrectly it may not work properly, and that is a wasted month and a wasted payment.

If a symptom needs investigating, that comes first. Unexplained weight change or abdominal pain needs a diagnosis before a weight-management medicine is layered on top.

Frequently asked questions

1. Is Wegovy available in the UK?
Yes, in both forms. The once-weekly injection has been licensed for weight management since 2023. The once-daily Wegovy pill was approved by the MHRA on 11 June 2026 and is available through regulated private providers, subject to a phased supply rollout.

2. Is the Wegovy pill the same as the injection?
Same active ingredient, semaglutide, in a different form. The injection is weekly and needs refrigeration. The tablet is daily and taken on an empty stomach after fasting. The strengths look very different because oral absorption is lower, but the two connect: 2.4 mg weekly by injection corresponds to 25 mg daily by tablet.

3. Is the Wegovy pill the same as Rybelsus?
No. Both are oral semaglutide, but Rybelsus is licensed only for type 2 diabetes at 3, 7 and 14 mg. The Wegovy pill is a higher-strength formulation licensed for weight management. They are not interchangeable.

4. Is Ozempic a weight-loss medicine?
Not in the UK. Ozempic contains semaglutide but is licensed here for type 2 diabetes. Prescribing it for weight loss is off-label. Wegovy is the licensed weight-management product.

5. Do I need a prescription?
Yes, for both forms. Wegovy is a prescription-only medicine in the UK and there is no legal route to obtaining it without a prescription following a clinical assessment.

6. What BMI do I need?
Privately, a BMI of 30 or above, or 27 to under 30 with at least one weight-related condition such as type 2 diabetes, prediabetes, high blood pressure, dyslipidaemia, sleep apnoea or cardiovascular disease. Lower thresholds may apply for some ethnic backgrounds.

7. Can I get Wegovy on the NHS?
The injection, potentially — but only through a specialist weight management service under NICE TA875, with a two-year funding limit. Not through your GP directly. The tablet is not NHS-funded and a NICE appraisal is under way.

8. How much does it cost privately?
At Slinic, the injection runs from £99.99 per pen at 0.25 mg to £209.99 at the 2.4 mg maintenance dose, with the 7.2 mg higher-dose pen at £329.99. The tablet runs from £99.00 per month at 1.5 mg to £179.00 at 25 mg. Fixed 2026 prices, no subscription. When comparing providers, compare total cost over twelve months at the dose you are likely to be on, including consultation, delivery and any subscription, rather than the advertised starting price.

9. What is the starting dose?
The injection starts at 0.25 mg once weekly. The tablet starts at 1.5 mg once daily. Both then titrate upward in steps with a minimum interval at each level.

10. How long does it take to reach the maintenance dose?
For the injection, typically around 16 weeks to reach 2.4 mg. For the tablet, a minimum of three months to reach 25 mg. Both can take longer if a step needs extending for tolerability.

11. Does everyone reach the top dose?
No. If appetite is well controlled and weight is coming down at a lower dose, there may be no clinical reason to increase. The aim is the lowest dose that works and that you tolerate.

12. How much weight could I lose?
In STEP 1, mean reduction with the 2.4 mg injection was approximately 14.9% over 68 weeks. In OASIS 4, mean reduction with the 25 mg tablet was approximately 16.6% over 64 weeks. These are trial averages with structured support, not individual predictions, and the two trials are not directly comparable.

13. What happens if I miss an injection?
If fewer than 5 days have passed, take it and continue your normal schedule. If 5 days or more, skip it and take the next dose as planned. Never take two to catch up.

14. What happens if I miss a tablet?
Skip it entirely and take the next one at the normal time the following morning. Do not take it later the same day once you have eaten, because the fasting condition needed for absorption has gone.

15. Why does the tablet have to be taken on an empty stomach?
Oral semaglutide absorption depends on the tablet dissolving in an empty stomach. Taking it with food, with any drink other than a sip of water, or too close to other oral medicines substantially reduces how much medicine reaches your bloodstream.

16. Can I switch from the injection to the tablet?
The licence allows people established on the 2.4 mg weekly injection to move directly to the 25 mg daily tablet on their prescriber's advice. From a lower injection dose it is a clinical judgement. The two must never overlap.

17. Can I switch from Wegovy to Mounjaro?
Yes, and it happens frequently. There is no official dose-equivalence between semaglutide and tirzepatide for weight management, so any switch is a clinical judgement based on your dose, duration, tolerability and response.

18. Can I drink alcohol?
There is no absolute prohibition, but alcohol can worsen nausea and reflux, contributes calories, affects blood glucose and adds to dehydration. Many people find they want it less. Discuss your own situation with your prescriber.

19. Does the injection need refrigeration?
Yes, before first use. The tablet does not need refrigeration at all, which is one of its practical advantages for travel.

20. Can I take Wegovy during pregnancy?
No. It is not recommended in pregnancy. If you are planning to conceive, treatment should be stopped well in advance — semaglutide has a long half-life, so the interval is longer than most people expect. Confirm it with your prescriber.

21. Will I regain weight if I stop?
Regain after stopping is common and well documented. STEP 4 showed that participants switched to placebo regained a substantial proportion of what they had lost. Sustained habits and a planned approach to stopping both help.

22. Can I use Wegovy before surgery?
Tell your surgical and anaesthetic team well in advance. Delayed gastric emptying increases aspiration risk under sedation or anaesthesia, and they will advise on stopping.

23. What is Wegovy 7.2 mg?
A licensed higher-dose option, roughly three times the standard 2.4 mg maintenance dose. It is not a starting dose — the full titration from 0.25 mg to 2.4 mg comes first, and 7.2 mg is only considered once you are established on 2.4 mg and your prescriber judges it appropriate. In the STEP UP trial it produced greater average weight reduction than 2.4 mg, with around a third of participants losing 25% or more.

24. Can I take Wegovy through the menopause?
Yes, if you meet the eligibility criteria and a prescriber agrees it is appropriate. Weight gain around menopause is common and has hormonal, muscle-mass and activity components. Semaglutide addresses appetite and intake; it does not treat the hormonal changes themselves, so if menopausal symptoms are the wider issue that is a separate conversation with your GP.

25. Does Wegovy affect fertility?
Not directly, but weight reduction can restore ovulation in people who were not previously ovulating, so fertility may return unexpectedly. Since semaglutide is not recommended in pregnancy, contraception should be planned before your first dose rather than after.

26. Can I take Wegovy if I have PCOS?
Often yes. PCOS is not itself on the licensed list of qualifying conditions, but insulin resistance, prediabetes or a qualifying BMI commonly accompany it. The fertility point above applies particularly here, so raise contraception at your assessment.

27. Will Wegovy work if I have already tried Mounjaro?
Possibly. Response to one GLP-1 medicine does not reliably predict response to another, and people switch in both directions for reasons of tolerability, cost or supply. Your prescriber will want to know what dose you reached, how long you were on it and why you stopped.

28. What should I do if I hit a plateau?
First, check the basics: consistency of doses, liquid calories, protein, sleep, and for tablet users whether the fasting routine has slipped. A few weeks without movement is normal variation rather than a plateau. If it persists at an adequate dose taken consistently, raise it at review — the answer may or may not be a dose increase.

29. Can I exercise normally on Wegovy?
Yes, and you should. Resistance training two or three times a week is the single most effective thing you can do to protect muscle while losing weight. Build gradually, stay hydrated, and scale back during periods of nausea or low intake rather than pushing through.

30. Can I take Wegovy on holiday?
Yes. The injection needs a cool bag, hand luggage and a copy of your prescription. The tablet needs none of that, which is one of its practical advantages. For long-haul travel, plan your weekly injection day or your daily fasted dose around the time change.

31. How long will I need to stay on it?
There is no fixed answer. Obesity is a chronic condition and some people need long-term treatment; others move to maintenance without medication. It should be reviewed periodically rather than decided at the start.

32. What happens at a monthly review?
Your prescriber looks at weight change, side effects, whether the dose is right, any new symptoms or medicines, and whether your other conditions need reviewing as your weight changes. It is also the point to raise anything that is not working, including cost.

33. Is the tablet cheaper than the injection?
At maintenance dose, yes. The 25 mg tablet is £179.00 a month against £209.99 for a 2.4 mg injection pen. The difference largely reflects the absence of cold-chain handling.

34. Can I split or crush the tablet?
No. It must be swallowed whole. If you cannot manage that, speak to your pharmacist — the injection is the alternative rather than modifying the tablet.

35. Do I need to take needles and sharps bins into account?
For the injection, yes. Needles and swabs are supplied with your treatment at Slinic. You will need a sharps bin for disposal, and you should check disposal arrangements before travelling abroad.

36. What if I want to stop?
Plan it with your prescriber rather than stopping abruptly. Appetite generally returns and regain is common, so a maintenance plan matters more than the stopping itself. If cost or side effects are prompting it, say so — there may be options you have not considered, including changing form or dose.

37. Can I use Wegovy alongside other weight-loss products?
Not alongside another GLP-1 medicine, ever — and that includes taking the injection and the tablet together. Tell your prescriber about any over-the-counter weight-loss product, supplement or herbal remedy you are using.

38. Does Wegovy cause muscle loss?
Weight loss from any cause includes some lean tissue. Adequate protein combined with resistance exercise substantially limits it, which is why both are emphasised throughout this guide rather than treated as optional extras.

39. Will my face change?
Facial volume loss is sometimes reported during rapid weight loss from any cause, not specifically as a drug effect. Losing weight at a steady rather than extreme rate, with adequate protein, is the practical answer.

40. Can I get Wegovy if I take antidepressants?
Usually, but it depends on which ones and on your wider history. Some psychiatric medicines are associated with weight gain and some interact with the picture in other ways. Disclose everything at assessment — it changes the advice rather than automatically preventing treatment.

41. Do I need blood tests before starting?
Not routinely for weight-management semaglutide. Your prescriber may request baseline or interval tests depending on your circumstances, for example if you have diabetes, kidney or liver concerns. It is a clinical judgement rather than a fixed requirement.

42. How quickly will it be delivered?
Orders are prepared promptly after clinical approval, with dispatch subject to stock, identity verification and delivery cut-off times. Injectable treatment is sent in temperature-controlled packaging.

43. What if my order is not approved?
You are not charged for treatment that is not approved, and the prescriber will explain the reason. Sometimes it is a request for more information rather than a refusal; sometimes it means a different treatment or route is more appropriate for you.

Summary

Wegovy is an effective option for eligible adults, with a large evidence base behind both the weekly injection and the newly licensed daily tablet. Neither is suitable for everyone, results vary considerably between individuals, and both work alongside dietary change and activity rather than instead of them.

The choice between injection and tablet is less about which is better and more about which you will actually take correctly and consistently. A weekly injection asks one action a week. A daily tablet asks a fasted morning routine every day, and taken incorrectly it may not work properly.

Obtaining either safely means a properly regulated UK pharmacy, a genuine clinical assessment, and complete honesty about your medical history. Price matters, but what happens after the first order matters at least as much.

If you have read this far, you should now understand how Wegovy works, who it is suitable for, what it costs, how the injection and the tablet differ, and what to expect from treatment. The next step is to complete a clinical assessment so one of our clinicians can determine whether Wegovy is safe and appropriate for you. It is free, it takes about two minutes, and a decision does not commit you to anything — if treatment is not right for you, we will tell you that and explain why. Start your clinical assessment.

Related guides

Mounjaro UK — our companion cornerstone guide to tirzepatide.

Wegovy Pill UK — the oral semaglutide option in detail.

Order Wegovy — current pricing and product information.

Weight Loss Injections UK — all treatments available at Slinic.

Mounjaro vs Wegovy — comparing the two medicines.

Wegovy to Mounjaro switching — how a switch is assessed.

Wegovy dosages explained — the full titration schedule.

Wegovy vs Saxenda — key differences for UK patients.

NHS weight loss injections 2026 — NHS eligibility explained.

Slinic vs Boots — how Slinic compares with Boots Online Doctor.

Slinic vs MedExpress — how Slinic compares with MedExpress.

Slinic vs Juniper — how Slinic compares with Juniper.

Slinic vs VOY — how Slinic compares with VOY.

Slinic vs Simple Online Pharmacy — how Slinic compares with Simple Online Pharmacy.

References

1. MHRA — First GLP-1 tablet for weight loss approved in the UK, 11 June 2026.
2. electronic Medicines Compendium — Wegovy 0.25, 0.5, 1, 1.7 and 2.4 mg FlexTouch, Summary of Product Characteristics.
3. electronic Medicines Compendium — Wegovy 7.2 mg solution for injection, Summary of Product Characteristics.
4. electronic Medicines Compendium — Wegovy Patient Information Leaflet.
5. Novo Nordisk UK — prescribing and medical information for Wegovy. [ADD SmPC REFERENCE FOR THE ORAL TABLET ONCE PUBLISHED ON emc]
6. NICE TA875 — Semaglutide for managing overweight and obesity, March 2023.
7. NICE — Oral semaglutide for managing overweight and obesity [ID6188], appraisal in progress.
8. NHS England — weight management service guidance.
9. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384(11):989–1002.
10. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA 2021.
11. Wharton S et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled phase 3b trial (NCT05646706). [VERIFY JOURNAL, YEAR AND DOI]
12. Wharton S, Lingvay I, Bogdanski P et al. Oral semaglutide 25 mg in adults with overweight or obesity (OASIS 4). N Engl J Med 2025;393(11):1077–1087.
13. MHRA Drug Safety Update — GLP-1 receptor agonists: strengthened warnings on acute pancreatitis.
14. MHRA Drug Safety Update — GLP-1 receptor agonists: potential side effects and awareness of misuse.
15. General Pharmaceutical Council — register of registered pharmacies and registered professionals.
16. British National Formulary — semaglutide.
17. Centre for Perioperative Care — guidance on GLP-1 receptor agonists and anaesthesia.
18. MHRA Yellow Card scheme — reporting suspected adverse drug reactions.
19. NHS.uk — obesity, BMI and treatment options.

All sources accessed 26 July 2026. Where sources conflict, current UK product information and MHRA guidance are treated as the source of truth.